AKBA Q1 2020 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$88M+21.8% YoY

Gross Profit

$61M68.7% margin

Operating Income

-$59M-66.8% margin

Net Income

-$61M-68.7% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

+27.2%

Cash Flow

Operating Cash Flow

-$90M

Free Cash Flow

-$90M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$788M

Total Liabilities

$391M

Stockholders' Equity

$396M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88M	$73M	+21.8%
Gross Profit	$61M	$41M	+46.7%
Operating Income	-$59M	-$76M	+22.2%
Net Income	-$61M	-$72M	+16.1%

Revenue Segments

License Collaboration And Other Revenue

$59M67%

Product

$29M33%